Management Advisory Council

  • Management Advisory Council

The BHCRI Management Advisory Council is composed of:

 

3 members from discovery/experimental research

3 members from clinical/translational research

2 members from population health research

2 members from behavioural research (to be interpreted broadly)

2 members from locally active supporting organizations

2 members from nationally active supporting organizations

4 members from the lay/business community

 

with significant representation of all four Atlantic Provinces

 

Members of the BHCRI Management Advisory Council:

    • Dr. Stephen Lewis, Chair, Assistant Scientific Director, Atlantic Cancer Research Institute, Moncton, NB

Dr. Stephen M. Lewis received his Ph.D. from Dalhousie University in 2004, where he studied the molecular mechanisms of vesicle trafficking in the budding yeast Saccharomyces cerevisiae. From 2004 until 2007, he pursued postdoctoral training in the molecular biology of translational control at the Apoptosis Research Centre, located at the University of Ottawa. Dr. Lewis joined the Atlantic Cancer Research Institute in 2008 as a Research Scientist and has been the Assistant Scientific Director since 2013.  At ACRI he oversees projects on the use of extracellular vesicles for cancer detection and therapeutics, as well as projects focused on the identification of novel therapeutic targets for cancer. Dr. Lewis’s independent research program is investigating how deregulated protein synthesis contributes to the development and progression of cancer, with a particular emphasis on metastatic breast cancer.

 

    • Ms. Leah CarrActing Co-CEO / Director, Research Programs and Human Development, New Brunswick Health Research Foundation, Fredericton, NB
    • Dr. Sheila Drover, Associate Professor of Immunology, BioMedical Sciences, Memorial University, St. John's, NL

 

 

 

 

 

    • Dr. Scott Grandy, Associate Professor, Kinesiology, School of Health and Human Performance, Dalhousie University, Halifax, NS

 

 

 

 

 

 

    • Ms. Heather Hogan, Patient Partner and Lung Cancer Advocate, NB

Heather HoganHeather Hogan (BA, Bed, Med) is a retired teacher and school administrator from Woodstock, New Brunswick.  Having been diagnosed with Stage 3a Adenocarcinoma lung cancer in 2012 (with a 15% chance of surviving five years), Heather knows first hand the importance of research. Heather is currently a Patient Partner with the Maritime SPOR Support Unit’s Scientific Leadership Committee and a Peer Support member with Lung Cancer Canada as part of their Programs Committee.“I believe in the advancement of all cancer research as well as promoting patient engagement in research.  I have seen the benefits of collaboration between stakeholders and I have also learned that research done in Atlantic Canada can compete both nationally and internationally.”

 

 

    • Dr. Andrew Reddick, Adjunct Professor, Sociology, UNB Fredericton

Andy ReddickDr. Andrew Reddick has a Ph.D. in Sociology and a Masters of Communications. He is an adjunct professor with the Department of Sociology, at the University of New Brunswick, Fredericton.

He has had extensive experience in the private and public sectors. In the private sector he founded and managed a number of companies, including: film and television production; public policy consulting; and more recently founded and managed a company facilitating Canada/European market entry. He has authored and co-authored a number of reports, articles and book chapters. Dr. Reddick has been a public speaker and commentator for radio, newspapers and television. He worked as a senior manager in the federal government at the National Research Council Canada where several of the research groups he supervised conducted health related research, including cancer. He volunteers for a number of organizations, including the Canadian Executive Service Organization.
 

    • Dr. Anthony ReimanCanadian Cancer Society Research Chair, University of New Brunswick; Medical Oncologist, Saint John Regional Hospital; Assistant Dean, Research, Dalhousie Medicine New Brunswick

Dr. Reiman is a medical oncologist at the Saint John Regional Hospital, where he provides front line cancer care including diagnosis, systemic therapy and opportunities for patients to participate in research protocols. He is the Canadian Cancer Society Research Chair at the University of New Brunswick, with a focus on novel therapies and biomarkers for multiple myeloma, lymphoma and lung cancer. As Professor of Medicine and Assistant Dean, Research for the Dalhousie Medicine New Brunswick program, Dr. Reiman has helped to build and maintain a new research program in New Brunswick including cardiovascular research, occupational medicine and oncology and the provision of research opportunities to medical students, undergraduates, residents and postdoctoral fellows. Dr. Reiman serves on the board of directors of the New Brunswick Health Research Foundation and the scientific advisory boards of Myeloma Canada and Lymphoma Canada. He is on several committees of the NCIC Clinical Trials Group and is a member of the US NCI Myeloma Steering Committee and the International Myeloma Working Group. Dr. Reiman has published over 180 peer reviewed cancer research manuscripts and presentations. ​
 

    • Dr. John Thoms, Radiation Oncologist, Dr. H. Bliss Murphy Cancer Centre, St. John's, NL

 

 

 

 

 

    • Dr. Sandra Turcotte, Professor, Chemistry and Biochemistry, Universite de Moncton, NB

Dr Sandra TurcotteBHCRI Senior Scientist Dr Sandra Turcotte, is an Assistant Professor at the Université de Moncton and researcher in residence at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal.

Her research focus is on developing new targeted therapy for kidney cancer. Her studies identify a small molecule that kills renal cancer cells and spare normal cells. Her laboratory uses a variety of methods in cell and molecular biology to study the role of autophagy in kidney cancer. Dr Turcotte holds a Canadian Cancer Society Research Chair in New Brunswick and is a KRESCENT New Investigator awardee.

 

    • Dr. Robin Urquhart, Assistant Professor, Department of Surgery, Dalhousie University, Halifax, NS

Dr. Robin Urquhart is an Assistant Professor and Ramia Scientist in the Department of Surgery at Dalhousie University, with cross-appointments in the Department of Community Health and Epidemiology and Division of Medical Education. She is also an Affiliate Scientist at the Nova Scotia Health Authority. Her research relates to understanding how scientific evidence moves into clinical practice and policy for persons diagnosed with cancer, and which strategies optimize its implementation, scale-up, and sustained use. The goal of her research is to increase the use of scientific evidence across settings so that important discoveries reach more people, more quickly, and in a more lasting way. Robin’s contributions to health research and health care have been recognized by numerous awards, including the 2014 Discovery Award for Science and Technology (Emerging Professional category).